Open AccessPeroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
Author(s) -
Fatima Safira Alatas,
Toshiharu Matsuura,
Antonius Hocky Pudjiadi,
Stephanie Wijaya,
Tomoaki Taguchi
Publication year - 2020
Publication title -
pediatric gastroenterology, hepatology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.44
H-Index - 19
eISSN - 2234-8646
pISSN - 2234-8840
DOI - 10.5223/pghn.2020.23.4.346
Subject(s) - ctgf , hepatic stellate cell , medicine , endocrinology , fibrosis , hepatic fibrosis , peroxisome proliferator activated receptor , agonist , growth factor , connective tissue , receptor , chemistry , biology , pathology
Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially regarding the cross-talk between PPAR-γ and other potent fibrogenic factors.